Literature DB >> 9867264

Validation of cause-of-death certification for outpatient cancers: the contrasting cases of melanoma and mycosis fungoides.

M A Weinstock1, J F Reynes.   

Abstract

The reported incidence of cancers typically diagnosed in the outpatient setting may underestimate their true frequency, but the validity of mortality estimates from many of these causes has not been studied in detail. The authors sought to evaluate the validity of mortality estimation from death certificates for two such cancers, melanoma and mycosis fungoides (a cutaneous lymphoma), using routinely collected cancer registry data for 1973-1994 from the Surveillance, Epidemiology, and End Results program. Their method estimates that 93% of the deaths attributable to melanoma were certified as due to melanoma but that only 60% of the deaths attributable to mycosis fungoides were so certified. Evaluation of the accuracy of cause-of-death certification in this manner is helpful in the interpretation of mortality statistics.

Entities:  

Mesh:

Year:  1998        PMID: 9867264     DOI: 10.1093/oxfordjournals.aje.a009607

Source DB:  PubMed          Journal:  Am J Epidemiol        ISSN: 0002-9262            Impact factor:   4.897


  13 in total

1.  Twenty-year trends in the reported incidence of mycosis fungoides and associated mortality.

Authors:  M A Weinstock; B Gardstein
Journal:  Am J Public Health       Date:  1999-08       Impact factor: 9.308

2.  Conditional survival estimates improve over time for patients with advanced melanoma: results from a population-based analysis.

Authors:  Yan Xing; George J Chang; Chung-Yuan Hu; Robert L Askew; Merrick I Ross; Jeffrey E Gershenwald; Jeffrey E Lee; Paul F Mansfield; Anthony Lucci; Janice N Cormier
Journal:  Cancer       Date:  2010-05-01       Impact factor: 6.860

3.  Efficacy and tolerability of anthracycline-based therapy in elderly patients with diffuse large B-cell lymphoma.

Authors:  Christine C Davis; Jonathon B Cohen; Katherine S Shah; Don A Hutcherson; Minal J Surati; Kelly Valla; Elyse H Panjic; Caitlin E Handler; Jeffrey M Switchenko; Christopher R Flowers
Journal:  Clin Lymphoma Myeloma Leuk       Date:  2014-12-31

4.  Melanoma epidemic: an analysis of six decades of data from the Connecticut Tumor Registry.

Authors:  Alan C Geller; Richard W Clapp; Arthur J Sober; Lou Gonsalves; Lloyd Mueller; Cindy L Christiansen; Waqas Shaikh; Donald R Miller
Journal:  J Clin Oncol       Date:  2013-09-16       Impact factor: 44.544

5.  Provider treatment intensity and outcomes for patients with early-stage bladder cancer.

Authors:  Brent K Hollenbeck; Zaojun Ye; Rodney L Dunn; James E Montie; John D Birkmeyer
Journal:  J Natl Cancer Inst       Date:  2009-04-07       Impact factor: 13.506

6.  Death certificates provide an adequate source of cause of death information when evaluating lung cancer mortality: an example from the Mayo Lung Project.

Authors:  V Paul Doria-Rose; Pamela M Marcus
Journal:  Lung Cancer       Date:  2008-06-30       Impact factor: 5.705

7.  Outcomes for lymphoid malignancies in the Nurses' Health Study (NHS) as compared to the Surveillance, Epidemiology and End Results (SEER) Program.

Authors:  Gregory A Abel; Kimberly A Bertrand; Craig C Earle; Francine Laden
Journal:  Hematol Oncol       Date:  2010-09       Impact factor: 5.271

8.  Racial differences in treatment and outcomes among patients with early stage bladder cancer.

Authors:  Brent K Hollenbeck; Rodney L Dunn; Zaojun Ye; John M Hollingsworth; Cheryl T Lee; John D Birkmeyer
Journal:  Cancer       Date:  2010-01-01       Impact factor: 6.860

9.  Assessing the utility of cancer-registry-processed cause of death in calculating cancer-specific survival.

Authors:  Chung-Yuan Hu; Yan Xing; Janice N Cormier; George J Chang
Journal:  Cancer       Date:  2013-02-13       Impact factor: 6.860

10.  End-of-life care quality outcomes among Medicare beneficiaries with hematologic malignancies.

Authors:  Pamela C Egan; Thomas W LeBlanc; Adam J Olszewski
Journal:  Blood Adv       Date:  2020-08-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.